CorMedix Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at CorMedix Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 6.30 $ to 12.70 $ · Last price: 7.70 $ (As of: September 18, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| CorMedix Inc CRMD | 0.6 | 3.7 | 2.0 | 90.2 | – | 617.0 | -30.0 |
| Vertex Pharmaceuticals Inc VRTX | 128.6 | 30.9 | 24.5 | 55.0 | 38.1 | 9.6 | 31.3 |
| Regeneron Pharmaceuticals Inc REGN | 81.5 | 19.7 | 13.1 | 44.5 | 20.7 | 1.0 | 31.8 |
| argenx NV ARGX | 61.6 | 37.8 | 31.5 | 59.1 | 32.0 | 89.6 | 35.3 |
| Moderna Inc MRNA | 61.1 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| Revolution Medicines Inc RVMD | 39.7 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 322.3 |
| BeiGene, Ltd. ONC | 39.7 | 62.6 | 34.1 | 88.9 | 19.1 | 40.2 | 2.3 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Alnylam Pharmaceuticals Inc ALNY | 31.8 | 60.3 | 28.4 | 79.7 | 23.0 | 65.2 | -47.0 |
| Median of companies shown | 39.7 | 31.5 | 19.6 | 59.1 | 21.8 | 9.6 | 31.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -25 | -25 | -3.25 | -22 | 18 | 22 |
| 2017 | 0 | -33 | -33 | -2.99 | -29 | -152 | 13 |
| 2018 | 0 | -27 | -27 | -1.51 | -24 | -179 | 19 |
| 2019 | 0 | -21 | -16 | -0.68 | -15 | -195 | 29 |
| 2020 | 0 | -27 | -22 | -0.77 | -22 | 44 | 49 |
| 2021 | 0 | -29 | -28 | -0.75 | -21 | 63 | 69 |
| 2022 | 0 | -31 | -30 | -0.74 | -24 | 55 | 62 |
| 2023 | 0 | -49 | -46 | -0.91 | -38 | 70 | 82 |
| 2024 | 43 | -22 | -18 | -0.30 | -51 | 85 | 119 |
| 2025 | 312 | 150 | 163 | 2.03 | 175 | 405 | 826 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.22 | – | 31 | 10,166.40 | 43.10 | -6 | -6 |
| 2025: Q1 | 0.30 | – | 39 | – | 52.80 | 20 | 20 |
| 2025: Q2 | 0.28 | – | 40 | 4,830.10 | 49.90 | 30 | 30 |
| 2025: Q3 | 1.26 | – | 104 | 810.20 | 104.10 | 31 | 30 |
| 2025: Q4 | 0.15 | -31.80 | 129 | 312.10 | 10.90 | 95 | 94 |
| 2026: Q1 | 0.42 | 38.70 | 127 | 226.10 | 30.30 | 42 | 42 |
| 2026: Q2 | 0.29 | 3.60 | 102 | 156.70 | 25.50 | 86 | 86 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Growth
Breakout & Setup
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.49 | 0.36 – 0.59 | 337 | -54.8% | 5 |
| 12/31/2027 | 0.06 | -0.16 – 0.23 | 287 | -17.5% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
With these assumptions (discount rate 10.0%, terminal growth 2.5%), no growth rate between -20.0% and 60.0% per year explains today’s market value — the reverse calculation yields no meaningful figure here.
| Free cash flow (last twelve months) | $251.7M |
|---|---|
| Market cap | $617.0M |
| Free cash flow in year ten | – |
| Terminal value as a share of market value | – |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 1,581.7%
- More than 10% revenue growth is expected for the coming year -14.7%
- Share count grows by less than 3% a year 25.9%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 672.5%
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 3.6%
- Net debt below twice EBITDA 1 m net cash
- Operating cash flow covers the profits of the last three years -13 m
- Return on capital at 15% or higher, or up versus two years ago 23.0%
- Insiders hold at least 10% or are net buyers 7.5%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 123.9%
- Exp. sales growth 3Y > 5% -4.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -82.8%
- Net debt < 4x EBIT 0.0x
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% –
- ROCE > 15% 23.0%
- Expected return > 10% -78.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 29, 2026 | Blum Susan | Chief Financial Officer | Other | 8,424 | 8.30 | 69,919 |
| Aug 29, 2026 | Hurlburt Elizabeth | Chief Operating Officer | Other | 8,076 | 8.30 | 67,031 |
| Aug 29, 2026 | Zelnick Kaufman Beth | Chief Legal Officer | Other | 8,424 | 8.30 | 69,919 |
The company
About the Company
CorMedix Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung therapeutischer Produkte für lebensbedrohliche Krankheiten und Zustände in den USA.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 191
- Headquarters
- Parsippany, NJ
- Address
- 389 Interpace Pkwy, 07054 Parsippany, United States
- Phone
- 908 517 9500
- Website
- cormedix.com
- IPO Date
- 03/25/2010
- ISIN
- US21900C3088
- Stock Split
- 1:5 on 03/26/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph Todisco MBA | CEO & Chairman of the Board of Directors | 1976 |
| Elizabeth Masson-Hurlburt B.A. | Executive VP and Chief Operating & Commercial Officer | 1979 |
| Kaufman Beth Zelnick Esq. | EVP, Chief Legal and Compliance Officer & Corporate Secretary | 1961 |
| Susan Blum | EVP & Chief Financial Officer | 1973 |
| Beth Steinbrenner | SVP & Chief Human Resource Officer | – |
| Matthew T. David M.D. | EVP & Chief Business Officer | 1978 |
| Donna Ucci | Senior VP & Head of Global Quality | – |
| Tushar Mukherjee | Senior VP & Head of Technical Operations | – |
| Peter Sullivan BCOP, Pharm.D. | Senior Vice President of Market Access | – |
| Jared L. Crandon Pharm.D. | Executive Director of Clinical Portfolio Management | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.